Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

NCT07561892 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Newly Diagnosed
Chemotherapy Effect

Interventions

DRUG: daunomycin/Idarubicin+ Silybinin
DRUG: daunomycin/Idarubicin

Sponsor

Fujian Medical University Union Hospital